AEON Biopharma announces Q3 2025 results via 8-K press release

AEON Biopharma furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025.

Rhea-AI Filing Summary

AEON Biopharma furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025. The company issued a press release with details, which is included as Exhibit 99.1 to this report.

The information in this update (including Exhibit 99.1) is furnished, not filed, under the Exchange Act. AEON’s Class A common stock trades on the NYSE American under the symbol AEON.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AEON (AEON) announce in this filing?

AEON announced financial results for the third quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1.

Which period do the results cover for AEON (AEON)?

The results cover the third quarter ended September 30, 2025.

Where can I find the detailed Q3 2025 results for AEON (AEON)?

Details are in the press release furnished as Exhibit 99.1 to this report.

Is the information in this AEON (AEON) update filed or furnished?

The information (including Exhibit 99.1) is furnished, not filed, under the Exchange Act.

What is AEON Biopharma’s trading symbol and exchange?

AEON’s Class A common stock trades on the NYSE American under the symbol AEON.

What exhibits are included with AEON’s report?

Exhibit 99.1 is the press release dated November 14, 2025; Exhibit 104 is the cover page Inline XBRL data file.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/14/2025 - 08:31 AM EST Learn about SEC filing dates

0001837607false00018376072025-11-142025-11-14

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

AEON Biopharma, Inc.

(Exact name of registrant as specified in its charter)

​

Delaware		001-40021		85-3940478
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

​

5 Park Plaza

Suite 1750

Irvine, CA 92614

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (949) 354-6499

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

​

​	​	​	​	​
Title of each class		Trading Symbol		Name of each exchange on which registered
Class A Common Stock, $0.0001 par value per share	​	AEON	​	NYSE American

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      ☐

​

​

​

​

​

​

Item 2.02. Results of Operations and Financial Condition.

​

On November 14, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) announced financial results for the third quarter ended September 30, 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (this “Report”).

The information furnished in this Item 2.02 of this Report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such a filing.

​

​

​

Item 9.01. Financial Statement and Exhibits.

​

(d) Exhibits.

​

​

Exhibit No.							Description
​		​					​
99.1							Press Release, dated November 14, 2025.
104		​					Cover Page Interactive Data File (embedded within the Inline XBRL document)

​

​

​

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​	​	​
​	AEON Biopharma, Inc.
Date: November 14, 2025	By:	/s/ Robert Bancroft
​	​	Robert Bancroft
​	​	Chief Executive Officer ​

​

​

​